Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Generate Biomedicines utilizes machine learning and generative biology to discover and develop novel protein therapeutics. Their platform aims to create protein-based drugs, with current pipeline candidates including treatments for severe asthma and cancer. The company positions itself as an innovator in addressing complex therapeutic challenges beyond traditional methods.
AI-generated summary. Not investment advice.